SignatureFD’s Actinium Pharmaceuticals ATNM Stock Holding History

SignatureFD’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8	Closed	-$47	–	3137
2023 Q3	$47	Hold	8	–	–	﹤0.01%	3155
2023 Q2	$59	Buy	+8	New	+$68	﹤0.01%	3186

Other funds holding ATNM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SignatureFD's ATNM Position: Q4 2023 in Review

SignatureFD sold out of Actinium Pharmaceuticals (ATNM) in Q4 2023, closing a stake of 8 shares — an estimated $47 sold.

SignatureFD first reported a position in ATNM in Q2 2023 and held it in 2 quarters. The position peaked at $59 in Q2 2023. 59 funds tracked by Wall St. Rank hold ATNM as of Q4 2023.

SignatureFD reported no remaining Actinium Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
SignatureFD sold 8 Actinium Pharmaceuticals shares in Q4 2023, an estimated $47.
SignatureFD first reported a position in Actinium Pharmaceuticals in Q2 2023 and held it in 2 quarters.
SignatureFD's Actinium Pharmaceuticals position peaked at $59 in Q2 2023.
59 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.